Skip to main content








Jack Bailey is the incoming CEO for G1 Therapeutics Inc., a RTP-based oncology company recently granted Breakthrough status and Priority Review by the FDA for their lead asset Trilaciclib, that seeks to fundamentally transform the chemotherapy experience for patients.  Prior to G1, Jack was President of GSK U.S., leading the U.S. Affiliate’s business in oncology, immunology, vaccines and respiratory for five years and spending a total of eleven years with the company.  Prior to GSK, Jack spent eighteen years at Eli Lilly & Company in a variety of senior leadership positions including Senior Vice-President for Account-based Markets (oncology and cardiovascular business units) and General Manager for South Africa.


Jack did his undergraduate work at Hobart College in Geneva, NY, earning a B.S. in Biology with a concentration in genetics and subsequently received his M.B.A. from the University of North Carolina at Chapel Hill’s Kenan-Flagler School of Business.  He is active in the life sciences and health care space serving as a Board member of Emergo Therapeutics, a RTP-based venture-backed biotech startup focused on inflammation.  He also is a Board member for the UNC Health Care System and an Advisor to the Harvard T.H. Chan School of Public Health.  He was a former Board member for the North Carolina Biotechnology Center, the North Carolina Health Quality Alliance and also past Chairmen of Board for the North Carolina Chamber of of Commerce.  He also is a past member of PhRMA, the life sciences industry national trade organization.  Jack lives in Raleigh with his wife Robin and has two college- age children.